Insight Molecular Diagnostics Inc. (LON:0KCC)

Market Cap	135.01M +391.3%
Revenue (ttm)	3.27M +520.9%
Net Income	-45.22M
EPS	-1.69
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41
Average Volume	1,284
Open	5.53
Previous Close	5.72
Day's Range	5.51 - 5.57
52-Week Range	2.02 - 7.77
Beta	1.35
RSI	42.06
Earnings Date	Mar 27, 2026

About LON:0KCC

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based tra...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2009
• Employees: 49
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0KCC

Financial Performance

In 2024, LON:0KCC's revenue was $1.88 million, an increase of 25.15% compared to the previous year's $1.50 million. Losses were -$60.93 million, 112.1% more than in 2023.

Financial numbers in USD